Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A

D. V.T. Catenacci, Y. K. Kang, H. H. Yoon, B. Y. Shim, S. T. Kim, D. Y. Oh, A. I. Spira, S. V. Ulahannan, E. J. Avery, P. M. Boland, J. Chao, H. C. Chung, F. Gardner, S. J. Klempner, K. W. Lee, S. C. Oh, J. Peguero, M. B. Sonbol, L. Shen, M. MoehlerJ. Sun, D. Li, M. K. Rosales, H. Park

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A'. Together they form a unique fingerprint.

Medicine & Life Sciences